IBOV 174,041.95 ▼ 1.52% IPSA 10,950.74 ▲ 0.31% IPC MEX 66,383.68 ▲ 0.21% MERVAL 3,283,854 ▼ 1.07% COLCAP 2,274.53 ▼ 0.38% BVL PERÚ 58,287.01 — — USD/BRL5.08▼ 0.24% USD/MXN17.49▲ 0.09% USD/CLP 948.45 — 0.00% USD/COP3,218▲ 0.16% USD/PEN3.40▲ 0.13% USD/ARS1,496▲ 0.47% USD/UYU40.14▲ 1.38% USD/PYG6,022▲ 1.26% USD/BOB11.18▲ 4.51% USD/DOP57.99▼ 0.28% USD/CRC449.17▲ 1.76% USD/GTQ7.63▲ 2.33% USD/HNL26.75▲ 0.82% USD/NIO36.62▲ 0.51% USD/VES740.37▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.29▲ 0.11% USD/TTD6.71▲ 0.92% EUR/BRL5.78▲ 0.08% BRENT 96.78 ▼ 3.88% WTI 89.31 ▼ 3.12% IRON ORE 161.91 — — COPPER 6.36 ▲ 0.83% GOLD 4,071 ▲ 0.60% SILVER 58.91 ▲ 1.92% SOY 1,254 ▲ 1.29% CORN 487.25 ▲ 5.01% WHEAT 678.00 ▼ 2.62% COFFEE 298.25 ▼ 3.60% SUGAR 14.76 ▲ 0.48% ORANGE JUICE 142.65 ▼ 2.83% COTTON 79.89 ▲ 0.06% COCOA 5,467 ▲ 3.13% BEEF 222.50 ▼ 1.29% CATTLE 341.45 ▼ 0.68% LITHIUM 67.81 ▼ 1.75% PETR4 42.21 ▼ 1.72% VALE3 75.24 ▼ 0.58% ITUB4 42.10 ▼ 1.08% BBDC4 18.48 ▼ 1.28% ABEV3 15.64 ▼ 1.76% BBAS3 20.35 ▼ 2.77% B3SA3 15.44 ▼ 1.34% WEGE3 45.99 ▲ 0.70% PRIO3 58.82 ▼ 2.84% SUZB3 41.84 ▼ 1.39% RENT3 36.89 ▼ 0.67% AZZA3 16.65 ▼ 2.35% CSAN3 3.80 ▼ 2.56% RAIZ4 0.26 ▼ 3.70% PCAR3 2.79 ▼ 2.79% GMAT3 3.79 ▼ 2.07% PSSA3 54.78 ▼ 0.72% CVCB3 1.34 ▲ 2.29% POSI3 3.55 ▼ 3.27% SLCE3 13.64 ▼ 0.94% NATU3 8.38 ▼ 2.10% BRKM5 6.10 ▼ 1.13% RANI3 7.95 ▲ 0.25% CSNA3 5.36 ▲ 1.13% CMIN3 5.69 ▼ 2.40% USIM5 8.48 ▼ 0.12% GGBR4 24.26 ▲ 0.83% ENEV3 24.90 ▼ 3.11% CPFE3 45.09 ▼ 2.44% CMIG4 10.98 ▼ 1.88% EQTL3 38.34 ▼ 1.74% LREN3 13.27 ▼ 0.75% VIVT3 35.47 ▲ 2.22% RAIL3 13.57 ▼ 2.79% KLABIN 17.52 ▼ 0.79% RAIA DROGASIL 17.98 ▼ 1.15% RDOR3 33.38 ▼ 0.86% HAPV3 9.92 ▼ 5.25% FLRY3 16.26 ▼ 1.93% SMTO3 15.05 ▼ 4.20% UGPA3 32.71 ▼ 2.04% VBBR3 35.10 ▼ 1.40% BBSE3 41.49 ▼ 2.15% BPAC11 54.67 ▼ 2.90% CURY3 29.35 ▼ 0.91% AERI3 2.04 ▲ 0.99% VIVARA 21.42 ▼ 0.14% COMPASS 24.76 ▼ 1.28% VAMOS 3.15 ▼ 1.87% SANB11 26.34 ▼ 1.09% ASAI3 7.85 ▼ 2.12% SBSP3 28.38 ▼ 1.29% WALMEX 48.00 ▲ 1.39% GMEXICO 207.28 ▼ 0.94% FEMSA 221.92 ▼ 0.19% CEMEX 21.18 ▼ 1.40% GFNORTE 193.04 ▲ 2.00% BIMBO 58.26 ▼ 1.39% TELEVISA 9.73 ▼ 0.61% AMX 22.80 ▲ 0.18% GAP 377.44 ▲ 0.26% ASUR 267.99 ▼ 0.69% OMA 226.14 ▼ 0.51% KOF 179.29 ▼ 0.23% GRUMA 268.70 ▼ 0.09% KIMBER 39.70 ▲ 1.10% SQM-B 65,350 ▼ 0.23% COPEC 6,330 ▲ 1.12% BSANTANDER 79.32 ▼ 0.85% FALABELLA 5,990 ▼ 1.12% ENELAM 85.49 ▲ 0.58% CENCOSUD 1,958 ▼ 0.51% CMPC 1,025 ▼ 2.47% BANCO CHILE 193.10 ▲ 1.25% LATAM AIR 23.88 ▲ 1.62% YPF 82,000 ▼ 0.58% GGAL 7,890 ▼ 0.69% PAMPA 5,515 ▼ 2.04% TXAR 675.00 ▼ 0.74% ALUAR 972.00 ▼ 1.07% TGS 9,765 ▼ 2.30% CEPU 2,365 ▼ 2.27% MIRGOR 16,525 ▼ 1.20% COME 42.41 ▼ 0.28% LOMA NEGRA 3,623 ▼ 3.78% BYMA 299.75 ▲ 2.48% TELECOM ARG 4,380 ▲ 1.27% ECOPETROL 16.01 ▼ 1.96% BANCOLOMBIA 86.01 ▼ 0.90% GRUPO AVAL 4.78 — 0.00% CREDICORP 388.77 ▲ 0.29% SOUTHERN COPPER 179.29 ▼ 1.61% BUENAVENTURA 30.91 ▼ 1.31% MERCADOLIBRE 1,801 ▲ 0.15% NUBANK 14.09 ▼ 0.70% XP 16.69 ▼ 0.83% PAGSEGURO 9.20 ▼ 2.75% STONE 10.76 ▼ 2.00% GLOBANT 31.30 ▲ 2.25% TECNOGLASS 45.30 ▲ 3.57% GAP AIRPORT 216.28 — 0.00% ASUR 267.99 ▼ 0.69% OMA AIRPORT 103.43 — 0.00% AMX ADR 26.01 — 0.00% FEMSA ADR 127.12 ▲ 0.03% CEMEX ADR 12.06 ▼ 1.63% PETROBRAS ADR 18.77 ▼ 1.21% VALE ADR 14.79 ▼ 0.27% ITAU ADR 8.28 ▼ 0.84% SANTANDER BR 5.30 ▼ 1.21% AMBEV ADR 3.06 ▼ 0.97% CSN 1.08 ▲ 1.89% GERDAU 4.81 ▲ 0.84% LATAM ADR 50.15 — 0.00% BTC 64,465 ▲ 0.57% ETH 1,880 ▲ 1.04% SOL 74.84 ▲ 1.30% XRP 1.10 ▲ 0.83% BNB 569.70 ▲ 0.95% ADA 0.17 ▲ 0.90% DOGE 0.07 ▲ 4.21% AVAX 6.79 ▲ 7.83% LINK 8.40 ▲ 0.86% DOT 0.82 ▲ 1.33% LTC 46.68 ▲ 0.77% BCH 209.60 ▼ 0.46% TRX 0.33 ▲ 0.15% XLM 0.18 ▼ 0.18% HBAR 0.07 ▼ 0.83% NEAR 1.79 ▼ 0.60% ATOM 1.39 ▼ 0.40% AAVE 92.40 ▼ 0.70% SELIC 14.25% EMBRAER 82.50 ▼ 1.08% EMBRAER ADR 64.93 ▼ 0.82% JBS 12.28 — 0.00% JBS BDR 62.04 ▲ 0.36% MBRF3 14.84 ▼ 4.81% MBRFY 2.94 ▼ 0.34% INTER 5.29 ▼ 3.11% EGX 53,932 ▼ 0.11% USD/ZAR16.82▲ 0.03% USD/NGN1,363▼ 0.44% NIKKEI 64,611 ▼ 2.73% CSI300 4,649 ▼ 1.67% HSI 24,963 ▼ 0.98% NIFTY 23,767 ▼ 0.43% KOSPI 6,691 ▼ 5.72% JCI 6,196 ▼ 1.88% USD/JPY163.79▼ 0.04% USD/CNY6.76▼ 0.15% DAX 25,099 ▲ 1.36% CAC 8,372 ▲ 0.88% FTSE 10,736 ▲ 0.91% MIB 51,802 ▲ 0.95% IBEX 19,585 ▲ 1.65% STOXX 644.51 ▲ 0.82% EUR/USD1.14▼ 0.02% GBP/USD1.33▲ 0.06% SPX 7,412 ▲ 0.05% DJI 51,947 ▲ 0.46% NDX 28,128 ▼ 1.15% RUT 2,930 ▼ 0.35% TSX 35,369 ▲ 0.50% VIX 18.58 ▼ 0.64% USD/CAD1.41— 0.00% US10Y 4.6790 ▼ 0.51% IBOV 174,041.95 ▼ 1.52% IPSA 10,950.74 ▲ 0.31% IPC MEX 66,383.68 ▲ 0.21% MERVAL 3,283,854 ▼ 1.07% COLCAP 2,274.53 ▼ 0.38% BVL PERÚ 58,287.01 — — USD/BRL 5.08 ▼ 0.24% USD/MXN 17.49 ▲ 0.09% USD/CLP 948.45 — 0.00% USD/COP 3,218 ▲ 0.16% USD/PEN 3.40 ▲ 0.13% USD/ARS 1,496 ▲ 0.47% USD/UYU 40.14 ▲ 1.38% USD/PYG 6,022 ▲ 1.26% USD/BOB 11.18 ▲ 4.51% USD/DOP 57.99 ▼ 0.28% USD/CRC 449.17 ▲ 1.76% USD/GTQ 7.63 ▲ 2.33% USD/HNL 26.75 ▲ 0.82% USD/NIO 36.62 ▲ 0.51% USD/VES 740.37 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.29 ▲ 0.08% USD/TTD 6.71 ▲ 0.68% EUR/BRL 5.78 ▲ 0.08% BRENT 96.78 ▼ 3.88% WTI 89.31 ▼ 3.12% IRON ORE 161.91 — — COPPER 6.36 ▲ 0.83% GOLD 4,071 ▲ 0.60% SILVER 58.91 ▲ 1.92% SOY 1,254 ▲ 1.29% CORN 487.25 ▲ 5.01% WHEAT 678.00 ▼ 2.62% COFFEE 298.25 ▼ 3.60% SUGAR 14.76 ▲ 0.48% ORANGE JUICE 142.65 ▼ 2.83% COTTON 79.89 ▲ 0.06% COCOA 5,467 ▲ 3.13% BEEF 222.50 ▼ 1.29% CATTLE 341.45 ▼ 0.68% LITHIUM 67.81 ▼ 1.75% PETR4 42.21 ▼ 1.72% VALE3 75.24 ▼ 0.58% ITUB4 42.10 ▼ 1.08% BBDC4 18.48 ▼ 1.28% ABEV3 15.64 ▼ 1.76% BBAS3 20.35 ▼ 2.77% B3SA3 15.44 ▼ 1.34% WEGE3 45.99 ▲ 0.70% PRIO3 58.82 ▼ 2.84% SUZB3 41.84 ▼ 1.39% RENT3 36.89 ▼ 0.67% AZZA3 16.65 ▼ 2.35% CSAN3 3.80 ▼ 2.56% RAIZ4 0.26 ▼ 3.70% PCAR3 2.79 ▼ 2.79% GMAT3 3.79 ▼ 2.07% PSSA3 54.78 ▼ 0.72% CVCB3 1.34 ▲ 2.29% POSI3 3.55 ▼ 3.27% SLCE3 13.64 ▼ 0.94% NATU3 8.38 ▼ 2.10% BRKM5 6.10 ▼ 1.13% RANI3 7.95 ▲ 0.25% CSNA3 5.36 ▲ 1.13% CMIN3 5.69 ▼ 2.40% USIM5 8.48 ▼ 0.12% GGBR4 24.26 ▲ 0.83% ENEV3 24.90 ▼ 3.11% CPFE3 45.09 ▼ 2.44% CMIG4 10.98 ▼ 1.88% EQTL3 38.34 ▼ 1.74% LREN3 13.27 ▼ 0.75% VIVT3 35.47 ▲ 2.22% RAIL3 13.57 ▼ 2.79% KLABIN 17.52 ▼ 0.79% RAIA DROGASIL 17.98 ▼ 1.15% RDOR3 33.38 ▼ 0.86% HAPV3 9.92 ▼ 5.25% FLRY3 16.26 ▼ 1.93% SMTO3 15.05 ▼ 4.20% UGPA3 32.71 ▼ 2.04% VBBR3 35.10 ▼ 1.40% BBSE3 41.49 ▼ 2.15% BPAC11 54.67 ▼ 2.90% CURY3 29.35 ▼ 0.91% AERI3 2.04 ▲ 0.99% VIVARA 21.42 ▼ 0.14% COMPASS 24.76 ▼ 1.28% VAMOS 3.15 ▼ 1.87% SANB11 26.34 ▼ 1.09% ASAI3 7.85 ▼ 2.12% SBSP3 28.38 ▼ 1.29% WALMEX 48.00 ▲ 1.39% GMEXICO 207.28 ▼ 0.94% FEMSA 221.92 ▼ 0.19% CEMEX 21.18 ▼ 1.40% GFNORTE 193.04 ▲ 2.00% BIMBO 58.26 ▼ 1.39% TELEVISA 9.73 ▼ 0.61% AMX 22.80 ▲ 0.18% GAP 377.44 ▲ 0.26% ASUR 267.99 ▼ 0.69% OMA 226.14 ▼ 0.51% KOF 179.29 ▼ 0.23% GRUMA 268.70 ▼ 0.09% KIMBER 39.70 ▲ 1.10% SQM-B 65,350 ▼ 0.23% COPEC 6,330 ▲ 1.12% BSANTANDER 79.32 ▼ 0.85% FALABELLA 5,990 ▼ 1.12% ENELAM 85.49 ▲ 0.58% CENCOSUD 1,958 ▼ 0.51% CMPC 1,025 ▼ 2.47% BANCO CHILE 193.10 ▲ 1.25% LATAM AIR 23.88 ▲ 1.62% YPF 82,000 ▼ 0.58% GGAL 7,890 ▼ 0.69% PAMPA 5,515 ▼ 2.04% TXAR 675.00 ▼ 0.74% ALUAR 972.00 ▼ 1.07% TGS 9,765 ▼ 2.30% CEPU 2,365 ▼ 2.27% MIRGOR 16,525 ▼ 1.20% COME 42.41 ▼ 0.28% LOMA NEGRA 3,623 ▼ 3.78% BYMA 299.75 ▲ 2.48% TELECOM ARG 4,380 ▲ 1.27% ECOPETROL 16.01 ▼ 1.96% BANCOLOMBIA 86.01 ▼ 0.90% GRUPO AVAL 4.78 — 0.00% CREDICORP 388.77 ▲ 0.29% SOUTHERN COPPER 179.29 ▼ 1.61% BUENAVENTURA 30.91 ▼ 1.31% MERCADOLIBRE 1,801 ▲ 0.15% NUBANK 14.09 ▼ 0.70% XP 16.69 ▼ 0.83% PAGSEGURO 9.20 ▼ 2.75% STONE 10.76 ▼ 2.00% GLOBANT 31.30 ▲ 2.25% TECNOGLASS 45.30 ▲ 3.57% GAP AIRPORT 216.28 — 0.00% ASUR 267.99 ▼ 0.69% OMA AIRPORT 103.43 — 0.00% AMX ADR 26.01 — 0.00% FEMSA ADR 127.12 ▲ 0.03% CEMEX ADR 12.06 ▼ 1.63% PETROBRAS ADR 18.77 ▼ 1.21% VALE ADR 14.79 ▼ 0.27% ITAU ADR 8.28 ▼ 0.84% SANTANDER BR 5.30 ▼ 1.21% AMBEV ADR 3.06 ▼ 0.97% CSN 1.08 ▲ 1.89% GERDAU 4.81 ▲ 0.84% LATAM ADR 50.15 — 0.00% BTC 64,465 ▲ 0.57% ETH 1,880 ▲ 1.04% SOL 74.84 ▲ 1.30% XRP 1.10 ▲ 0.83% BNB 569.70 ▲ 0.95% ADA 0.17 ▲ 0.90% DOGE 0.07 ▲ 4.21% AVAX 6.79 ▲ 7.83% LINK 8.40 ▲ 0.86% DOT 0.82 ▲ 1.33% LTC 46.68 ▲ 0.77% BCH 209.60 ▼ 0.46% TRX 0.33 ▲ 0.15% XLM 0.18 ▼ 0.18% HBAR 0.07 ▼ 0.83% NEAR 1.79 ▼ 0.60% ATOM 1.39 ▼ 0.40% AAVE 92.40 ▼ 0.70% SELIC 14.25% EMBRAER 82.50 ▼ 1.08% EMBRAER ADR 64.93 ▼ 0.82% JBS 12.28 — 0.00% JBS BDR 62.04 ▲ 0.36% MBRF3 14.84 ▼ 4.81% MBRFY 2.94 ▼ 0.34% INTER 5.29 ▼ 3.11% EGX 53,932 ▼ 0.11% USD/ZAR 16.82 ▲ 0.04% USD/NGN 1,363 ▼ 0.24% NIKKEI 64,611 ▼ 2.73% CSI300 4,649 ▼ 1.67% HSI 24,963 ▼ 0.98% NIFTY 23,767 ▼ 0.43% KOSPI 6,691 ▼ 5.72% JCI 6,196 ▼ 1.88% USD/JPY 163.79 ▲ 0.02% USD/CNY 6.7617 ▼ 0.07% DAX 25,099 ▲ 1.36% CAC 8,372 ▲ 0.88% FTSE 10,736 ▲ 0.91% MIB 51,802 ▲ 0.95% IBEX 19,585 ▲ 1.65% STOXX 644.51 ▲ 0.82% EUR/USD 1.1375 ▼ 0.06% GBP/USD 1.3321 ▲ 0.04% SPX 7,412 ▲ 0.05% DJI 51,947 ▲ 0.46% NDX 28,128 ▼ 1.15% RUT 2,930 ▼ 0.35% TSX 35,369 ▲ 0.50% VIX 18.58 ▼ 0.64% USD/CAD 1.4092 ▲ 0.09% US10Y 4.6790 ▼ 0.51%
since 2009
Sunday, July 26, 2026

Brazil Life & Society

Hydroxychloroquine, Experimental Treatment and Weapon in Bolsonaro and Trump “Culture War”

By · April 9, 2020 · 7 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – Scientists from all over the world are racing against the clock for a cure and a vaccine for the novel coronavirus. For now, nothing definitive on the front but experimental therapies, some of them considered promising, but still lacking sufficient studies to be considered for general recommendation.

Among them is the use of chloroquine or hydroxychloroquine, drugs to fight malaria, arthritis and lupus, in patients with Covid-19. In Brazil -and in the US- the topic is not only scientific: it has fostered a political clash and become a weapon in the “cultural war” of both polarized countries.

Both Jair Bolsonaro and Donald Trump have decided to become front-line advocates of the substances, even if the technical section of the governments they command does not endorse the recommendations with the same emphasis.
Both Jair Bolsonaro and Donald Trump have decided to become front-line advocates of the substances, even if the technical section of the governments they command does not endorse the recommendations for general use. (Photo internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

Both Jair Bolsonaro and Donald Trump have decided to become front-line advocates of the substances, even if the technical departments of the governments they command do not endorse the recommendations with the same emphasis.

The experts’ greatest concern, there as here, is that early disclosure of any possibly positive results will lead to self-medication or indiscriminate use before all risks are fully addressed.

In Brazil, President Jair Bolsonaro, who is completely against social isolation measures to fight the spread of the virus, has insisted on the issue and is already taking for granted the success of using the drug to treat the Covid-19 disease.

Speaking on Wednesday in a national network, the President said he had reached an agreement with the Prime Minister of India, Narendra Modi, for Brazil to continue receiving raw material for the production of hydroxychloroquine.

“So that we can treat Covid-19 patients, as well as malaria, lupus and arthritis,” he said. On the other side of the debate, there is a group of scientists and doctors, including Health Minister Luiz Henrique Mandetta, who are calling for caution and are trying to expedite research to reach a safer conclusion regarding the generalized use of these drugs in the pandemic.

Mandetta has been saying that more time for research on the drug is necessary, although he has already released the substance for treatment of patients in advanced and intermediate stages of the disease. As a rule, doctors in Brazil are authorized to prescribe chloroquine and hydroxychloroquine to people with coronavirus provided there is formal patient consent.

On Wednesday, the Minister again considered that the substance may produce still unknown side effects, particularly in the elderly and in those who have not been tested for Covid-19 and may be suffering from other conditions.

“Will it protect or will they [elderly] have cardiac arrhythmia, need ICU [Intensive Care Center] and have acute myocardial infarction?”, he asked. The Minister said he asked the Federal Medicine Council to take a position on the substance’s effectiveness by April 20th.

In Brazil, there are two studies underway on chloroquine and hydroxychloroquine, analogous drugs, recommended for the treatment of malaria, rheumatism and lupus. One of them is the Covid Brazil Coalition, coordinated by Albert Einstein Hospital, Sírio Libanês HCor and BRICNet, a network that carries out studies in the area of intensive care medicine.

The other is coordinated by Fiocruz (Oswaldo Cruz Foundation) and although it has not yet been completed, preliminary results suggest that the death rate of those who used chloroquine in treatment is the same as those who did not. Both studies are being monitored by the Ministry of Health and are part of a set of nine ongoing research studies on treatments for the disease.

However, according to an ANVISA document, a number of international publications already point out that the drug may be capable of acting against the coronavirus, preventing its replication in the organism. Nevertheless, the same document warns that the borderline between therapeutic and toxic doses of the drug is narrow. Therefore, conclusive studies are still required.

“We do not know if there is a group at higher risk [to the adverse consequences of the drug], for instance,” says Antônio Carlos Lopes, president of the Brazilian Society of Medical Clinics and full professor of the Paulista Medical School. “But I’ve never seen any side effects. I’ve been prescribing this drug for 40 years and I’ve never recorded any adverse effects”.

As a rule, doctors in Brazil are authorized to prescribe chloroquine and hydroxychloroquine to people with coronavirus provided there is formal patient consent.
As a rule, doctors in Brazil are authorized to prescribe chloroquine and hydroxychloroquine to people with coronavirus provided there is formal patient consent. (Photo internet reproduction)

But Denizar Vianna, secretary of Science, Technology and Strategic Health Supplies of the Ministry of Health, stressed during a press conference that the main side effect of both drugs is the potential to cause cardiac arrhythmia.

“The heart is a bomb that depends on the activation of its own electrical system. This drug can produce an increase in one of these electrical phases of the heart and provide a favorable environment for an arrhythmia that can be potentially fatal,” he said this week.

Despite the absence of conclusions, the government has already been mobilizing to increase the production of the drug, while taking steps to avoid self-medication and guarantee its supply. As of March 20th, both chloroquine and hydroxychloroquine required a double prescription to be purchased at drugstores.

The measure will be particularly useful so that patients who already use the drug are not left unattended if there is a mass demand in pharmacies. In parallel, the chemical laboratories of the Armed Forces have announced that they are increasing the production of chloroquine, which may reach 500,000 pills a week. And the Ministry of Health has already announced the distribution of the drug to the states.

According to the São Paulo Secretary of Health, José Henrique Germann, the state received 200,000 pills that have already been distributed to hospitals.

Doctors linked to opposition targeted

Despite the worldwide effort to find scientific conclusions about the drug, Bolsonaro continues using the potential for a treatment for the disease as political ammunition.

“For 40 days I have been talking about the use of hydroxychloroquine in the treatment of COVID-19. I have always tried to take care of people’s lives first, but also by worrying about preserving jobs. I have made contact with dozens of doctors and heads of state in other countries over this time,” the President Tweeted on Wednesday.

“More and more the use of chloroquine is appearing as something effective. Two renowned doctors in Brazil have refused to divulge what cured them of COVID-19. Would these be political issues, since one belongs to the team of the São Paulo Governor?”, he said, in reference to the management of his political opponent, João Doria.

The President’s attacks had two clear targets. These were two of the greatest medical big guns in the country, Roberto Kalil Filho, cardiologist at the Sírio Libanês Hospital, and infectologist David Uip, coordinator of the São Paulo Coronavirus Contingency Center.

Both were recently cured of Coronavirus. Kalil Filho was discharged on Wednesday after a ten-day hospitalization. On the same day, he said that he used hydroxychloroquine after one of the doctors treating him proposed its use. He pondered, however, that the drug was only one of those he used to be treated, along with others, and that he does not intend to influence anyone’s treatment.

there is a group of scientists and doctors, including Health Minister Luiz Henrique Mandetta, who are calling for caution and are trying to expedite research to reach a safer conclusion regarding the use of these drugs in the pandemic.
There is a group of scientists and doctors, including Health Minister Luiz Henrique Mandetta, who are calling for caution and are trying to expedite research to reach a safer conclusion regarding the use of these drugs in the pandemic. (Photo internet reproduction)

Kalil’s statement further leveraged the provocations against David Uip, who had already been pressured to tell if he had used the drug. Returning to work this week after 15 days away, and knowing that Bolsonaro’s publication on Twitter was about him, Uip argued.

“President, respect my right not to disclose my treatment,” he said during a press conference on Wednesday in São Paulo. “There is no relevance in what I took or did not take. “What is important is that I did not self-medicate. Everything else is absolutely personal”.

Uip, who was eventually treated by Kalil before the cardiologist became ill, said he would not disclose his treatment, an entitlement of any patient. On social media an alleged prescription of chloroquine given to a patient by Uip’s clinic was even published.

The doctor confirmed the veracity of the document, stating that the prescription would have been leaked by someone in his office. At the press conference, however, he stated that he will take “legal and appropriate measures to this invasion of my privacy”.

In any event, the issue stirs up virtual tensions in favor and against Bolsonaro, or the drug, and this in itself, is not a negligible side effect on the Bolsonarist modus operandi. In the US, political analysts argue that Trump is following his usual script: to cling to an “optimistic” and “anti-system” view, this time in relation to the pandemic.

If the drugs prove to be effective, the US president may say that he has anticipated the experts “of the system”.

If it fails to work, the White House occupant has experience only in shifting the focus of the conversation and ignoring the preceding campaign. It would not be the first time that Bolsonaro has followed his script.

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.